Market Overview

OXiGENE Says Phase 2 Data on ZYBRESTAT May Produce Transient Cut

Share:
Related OXGN
OXiGENE Receives Guidance from FDA Supporting Phase 3 Trial of Fosbretabulin/Bevacizumab Combination in Platinum-Resistant Ovarian Cancer
OXiGENE Announces Issuance of U.S. Patent for OXi4503 in Acute Myeloid Leukemia
Midday Gainers / Losers (Seeking Alpha)

OXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the presentation today of data from a Phase 2 trial of ZYBRESTAT (fosbretabulin) in patients with polypoidal choroidal vasculopathy (PCV), which has features similar to age-related macular degeneration (AMD), a degenerative eye disease.

Posted-In: News FDA

 

Related Articles (OXGN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters